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Parawixia bistriataThe neurobiological activity of Parawixin 10, isolated from Parawixia bistriata spider venom, was investigated.
Cannulas were implanted in the lateral ventricles of Wistar rats (200–250 g, n=6–8 per group) to perform
anticonvulsant and behavioral assays, and synaptosomes from cerebral cortices of maleWistar rats were used
for neurochemical studies. The results indicate that pretreatment with Parawixin 10 prevents the onset of
seizures induced with kainic acid, N-methyl-D-aspartate, and pentylenetetrazole in a dose–response manner.
Lower doses of Parawixin 10 signiﬁcantly increased the latency to onset of kainic acid-, pentylenetetrazole-,
and N-methyl-D-aspartate-induced seizures. There were maximum increases of 79% in L-[3H]glutamine
uptake and 40% in [3H]glycine uptake; [3H]GABA uptake did not change. The ﬁndings demonstrate that this
novel compound from P. bistriata venom exerts a pharmacological effect on the glutamatergic and glycinergic
systems.FFCLRP/USP, Departamento de
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In recent decades, several molecules puriﬁed from venom,
especially polyamines and peptides, have aided the elucidation of
physiological intrinsic properties of ion channels, neurotransmitter
receptors, and transporters [1–3]. However, despite their great
potential as pharmacological tools, only small parts of these
compounds have been studied and the vast majority of molecules
remain unexplored.
Parawixia bistriata spider venom has been the object of intense
investigation by our laboratory [4,5]. When applied to the rat's central
nervous system (CNS), P. bistriata crude venom induces limbic
seizures [6], whereas deproteinized venom blocks generalized
tonic–clonic seizures induced with the GABAergic antagonists
bicuculline, picrotoxin, and pentylenetetrazole (PTZ). Moreover, the
addition of P. bistriata spider venom to synaptosomes from rat
cerebral cortex increases L-glutamate (L-Glu) uptake and inhibits
GABA uptake [5,7].Fontana et al. [4] isolated and identiﬁed Parawixin 1 (formerly
PbTx 1.2.3), which increases L-Glu uptake in rat cortical synaptosomes
and protects retinal neurons from ischemic damage. Parawixin 1
promotes the direct and selective enhancement of L-Glu inﬂux by the
EAAT2 transporter subtype, but does not interfere with the afﬁnity of
the transporter for its co-substrates and Na+ ions, as demonstrated
using cloned liposomes and COS cells [8]. According to Salazar and
Fahlke [9] the selectivity and speciﬁcity of Parawixin 1 make it a
starting point in the design of small molecules to be used in the
treatment of pathological conditions caused by alterations of L-Glu.
The fractionation of P. bistriata venom also revealed a potent
inhibitor of GABA and glycine uptake, namely, FrPbAII (2-amino-5-
ureidopentanamide). According to Beleboni and co-workers [5],
FrPbAII acts directly on these transporters rather than on ion channels
permeable to Na+, K+, or Ca2+, GABA transaminase, or reverse
transport. Bioassays have shown that FrPbAII (formerly PbTx 2.2.1)
blocks tonic–clonic seizures induced with bicuculline [7], PTZ, kainic
acid (KA), and pilocarpine [10]. Also, when injected into the
substantia nigra and pars reticulata, FrPbAII inhibits generalized
seizures induced by GABAergic blockade of the area tempestas in the
pyriform cortex, and when injected into the dorsal hippocampus, it
exerts anxiolytic effects [11]. FrPbAII is also neuroprotective after
intravenous administration in Wistar rats submitted to experimental
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injected into vitreous, it completely inhibits retinal layer neuronal
death induced by ischemia and ischemia–reperfusion, being 100
times more potent than nipecotic acid (unpublished data).
Considering that neurotransmitter transporter malfunction is
closely associated with severe pathological conditions such as
epilepsy, Alzheimer's disease, and ischemia, P. bistriata spider
venom could be considered an interesting source of probes for
novel therapeutic strategies. In the light of all these facts, the aim of
this study was to identify a novel compound from P. bistriata venom
that acts on neurotransmitter transport and inhibits seizures induced
with chemoconvulsants.
2. Material and methods
2.1. Spider collection and venom fractionation
Nests of P. bistriata collected in the rural areas neighboring
Ribeirão Preto, São Paulo, Brazil, were frozen at −4 °C, taken to the
laboratory, and kept at −20 °C. Glands and venom reservoirs were
removed, homogenized in CH3CN:H2O (1:1; v/v), and centrifuged at
8000 g for 10 minutes at 4 °C. Supernatants were collected and
ﬁltered in membranes with a 3000-Da cutoff (Millipore, Microcon,
USA) under centrifugation at 8000 g and 4 °C until complete ﬁltration.
Next, the extract was lyophilized, weighed, and submitted to
fractionation.
Dry extract was dissolved in ultrapure water of Milli-Q grade
containing 0.1% TFA. The solution was subjected to reverse-phase
high-performance liquid chromatography (RP-HPLC; Shimadzu,
Japan) using an ODS C18 column (15 μm, 20×250 mm; Phenom-
enex-Jupiter, USA) at the ﬂow rate of 8.0 mL/min and a UV light
detection system at 214 nm. Initially, an isocratic gradient was run
with 1% CH3CN:H2O (v/v) containing 0.1% TFA for 10 minutes. Next, a
linear gradient from 1 to 60% CH3CN for 60 minutes was performed.
Fractions were collected, lyophilized, weighed, and used in bioassays.
2.2. Purity of fractions
Dry fractions were dissolved in 50% CH3CN:H2O (v/v) containing
0.1% formic acid (v/v). Molecular masses were determined by positive
electrospray ionization (ESI+) on a high-resolution spectrometer.
Fractions were injected with the aid of an infusion pump at a ﬂow of
10 kL/minute. ESI-MS spectra were acquired on an UltrOTOF appara-
tus (Bruker Daltonics, Billerica, USA) in the continuous acquisition
mode, scanning from m/z 50 to 2000 with a scan time of 5 seconds.
Calibrations were made using intact horse heart myoglobin (Sigma–
Aldrich, USA) and its typical cone-voltage-induced fragments.
2.3. Animals and surgery
Male Wistar rats (220–250 g), from the animal house of the
Campus Universitarius of the University of São Paulo at Ribeirão Preto
were used in the assays. The animals were kept in pairs in wire-mesh
cages in a roomwith a 12-hour dark/light cycle (lights on at 7:00 AM)
with water and food cubes ad libitum. Animals were maintained in
accordance with the Brazilian Society for Neuroscience and Behavior
ethical statements that follow the guidelines for animal care prepared
by the Committee on Care and Use of Laboratory Animal Resources,
National Research Council (USA). Luminosity and temperature (22 °C)
were kept constant in the housing and experiment rooms. Efforts
were made to minimize the potential suffering of experimental
subjects. Approval was obtained from the Ethics Committee for Care
and Use of Laboratory Animals from Campus Universitarius of the
University of São Paulo at Ribeirão Preto (CEUA No. 10.1.619.53.3).
All animals were implanted with stainless-steel guide cannulas
(10 mm) in the right lateral ventricle under ketamine (60 mg/kg;Agener União, Brazil) and xylazine (8 mg/kg; Calier, Spain) anesthe-
sia. The coordinates used were 0.9 mm posterior to bregma, 1.6 mm
lateral from midline, and 3.4 mm ventral from the surface of the skull
according to the atlas of Paxinos andWatson [12]. Next, animals were
placed in a stereotactic frame (Stoelting, USA) and injected percuta-
neously before surgical incision with 0.1 mL of 2% lidocaine
hydrochloride containing epinephrine at 1:200.000 (Astra Química,
Brazil). Cannulas and stainless-steel screws, for anchoring, were ﬁxed
to the skull with dental acrylate. Each cannula was sealed with a
stainless-steel wire to avoid obstruction. After surgery, animals were
injected with ﬂunixin meglumine (1 mg/kg; Schering–Plough Animal
Health, Brazil) to minimize pain. The animals were then allowed to
rest for 5–7 days to recover from surgery.
2.4. Anticonvulsant screening
CD97 doses of chemoconvulsants were used, that is, the dose
producing hindlimb tonic convulsions in 97% of animals. These doses
were previously established in dose–response experiments for each
convulsant [13].
Before injections, animals were placed in the open ﬁeld for
10 minutes. Rats were divided into groups (n=6–8). Three different
doses of Parawixin 10were testedwith each convulsant: Parawixin 10
at 0.25, 0.5, 1.0, and 1.5 μg/μL, 10 minutes before KA (0.8 μg/μL);
Parawixin 10 at 1.0, 2.0, and 5.0 μg/μL, 10 minutes before NMDA
(20 μg/μL); Parawixin 10 at 1.0, 2.0, 3.0, and 6.0 μg/μL, 10 minutes
before PTZ (85 mg/kg, 0.2 mL, ip), all injected intracerebroventricu-
larly in a volume of 1 μL. In separate groups of animals, one-milliliter
volumes of diazepam (2, 5, and 10 mg/kg) and saline were injected
intraperitoneally.
The ﬁnal volume for drugs delivered by the intracerebroventri-
cular routewas 1 μL over a 1-minute period, whereas PTZwas injected
in a volume of 0.2 mL into the loose fold of the neck. After drug
administration, animals were placed in the arena (open ﬁeld) and
ﬁlmed for 30 minutes. Next, rats were packed in individual cages until
total recovery.
Kainic acid- and NMDA-induced seizures were scored as follows:
0=no seizure activity; 1=jaw movements; 2=head myoclonus;
3=hindlimb myoclonus; 4=elevation; 5=elevation and fall;
6=ear and head myoclonus, clonic movements, sequential events
of elevation and fall; 7=rolling, violent jumps, and vocalization;
8=all behaviors of class 7 followed by periods of hypertonus [14].
Latency to the onset of seizures and percentage of animals protected
against score 8 seizures were the parameters used to analyze the
anticonvulsant effects.
Seizures induced by PTZ administration were analyzed according
to the Lamberty and Klitgaard [15] index, considering behavior of the
convulsing animals as well as latency to onset of tonic–clonic seizures.
2.5. Spontaneous locomotor activity and behavioral assays
On themorning of the experiments, Wistar rats (n=6, 200–250 g)
were transferred to the experimental rooms and allowed a 10-minute
period for acclimation. Next, they were randomly assigned to
treatment groups and injected intracerebroventricularly with either
Parawixin 10 (2.5, 5.0, or 10 μg/μL) or saline 15 mM, with the aid of a
Hamilton syringe moved by an infusion pump (Insight, Brazil)
injecting a volume of 1 μL/1 minute. After 10 minutes, rats were
gently placed in an open ﬁeld consisting of an acrylic arena 60 cm in
diameter and 12 cm high. Animals were monitored by a video camera
interfaced with a VCR and a monitor placed in the adjacent room for
20 minutes, after which they were returned to their home cages and
remained under observation for 2 hours.
Spontaneous locomotor activity of the animals was determined by
counting the line crossings in the open ﬁeld of each animal along four
time windows (0–5, 5–10, 10–15, and 15–20 minutes). Moreover, the
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grouped according to Speller and Westby [16] with modiﬁcations as
follows: exploratory (EX), grooming (GR), rearing (RE), and inactivity
(IN).2.6. Motor impairment: ataxia
To evaluate the potential animal motor impairment, Wistar rats
(n=6, 200–250 g) were assayed in the rotarod test (Ugo Basile, Italy),
which consists of a rotating bar (Ø 5 cm) driven by a motor. The day
before the test, rats were trained to maintain their equilibrium on the
rotating rod. The training consisted of three consecutive 1-minute
attempts at 4 rpm. On the morning of the test, rats were again tested
on the rotarod and only animals able to maintain their equilibrium on
the rod were retained for the experimental procedure. Parawixin 10
(7.5, 15, 30, 45, 60, and 75 μg/animal) or saline 15 mM was
administered intracerebroventricularly in a volume of 1 μL/minute,
10 minutes before the test. The latencies to fall off the rod at 5, 10, 15,
20, 25, 30, 40, 50, 60, 70, 80, and 90 minutes were recorded. Moreover,
the number of animals falling on three consecutive attempts was used
to calculate the doses at which 50% of the animals displayed toxicity
(TD50). After assays, rats were euthanized with overdoses of
anesthetic.2.7. Histology
At the end of the behavioral experiments, the animals were killed
with an overdose of sodium thiopental (Cristalia, Brazil) and injected
intracerebroventricularly with 1 μL of toluidine blue dye to mark the
correct site of injection. Brains were immediately removed and placed
in 4% formaldehyde solution. Later, they were manually cut to check
the position of the cannula.2.8. [3H]Glutamate, [3H]glycine, and [3H]GABA uptake into cortical
synaptosomes
Cerebral cortices from male Wistar rats (200–250 g) were rapidly
removed and homogenized in ice-cold 0.32 M sucrose using Potter–
Elhvejen Labo Stirrer LS-50 Yamato-type equipment. The sample was
centrifuged for 10 minutes at 1700 g (4 °C), and the supernatant
centrifuged for 20 minutes at 21,200 g (4 °C). The pellet was
resuspended in Krebs–phosphate buffer (in mM: NaCl 124, KCl 5,
KH2PO4 1.2, CaCl2 0.75, MgSO4 1.2, Na2HPO4 20, glucose 10, pH 7.4),
referred to as synaptosome P2 fraction, and used in the L-Glu, glycine,
and GABA uptake assay. Protein content was determined by the Lowry
et al. [17] method, as modiﬁed by Hartree [18]. Synaptosomes were
resuspended in Krebs–phosphate buffer and pre-incubated for
5 minutes at 37 °C (for [3H]glutamate and [3H]glycine) or for
15 minutes at 25 °C (for [3H]GABA) in the absence or presence of 6–12
increasing concentrations of Parawixin 10 (from 10–11 to 101 μg/mL).
Uptake assays were initiated by addition of [3H]glutamate, [3H]
glycine, and [3H]GABA (10 nM, ﬁnal concentration: 1 mCi/mmol;
Amersham Biosciences, USA) to synaptosomal suspensions (100 μg
of protein ml–1), and incubation for 3 minutes at the aforementioned
temperatures for each neurotransmitter, according to Pizzo et al.
[19]. The ﬁnal volume of each tube was 500 μL. All reactions were
stopped by centrifugation (3000 g, 3 minutes at 4 °C). Supernatants
were discarded; pellets were washed twice with ice-cold distilled
water, homogenized in 10% trichloroacetic acid (TCA), and centri-
fuged (3000 g, 3 minutes at 4 °C). Aliquots of supernatants were
transferred to scintillation vials containing 5 mL of the biodegradable
scintillation cocktail ScintiVerse (Fisher Scientiﬁc, USA), and their
radioactivity was quantiﬁed in a scintillation counter (LS-6800;
Beckman Coulter, USA) with a counting efﬁciency of 50% for 3H.2.9. Statistical analysis
Probit analysis [20] was used to calculate ED50 and TD50 values
(with 95% conﬁdence intervals). All parametric data were submitted
to one-way analysis of variance (ANOVA) followed by the Newman–
Keuls post hoc test. The frequencies of protected animals in the
anticonvulsant assays were analyzed using the χ2 test and are
expressed as the number of animals exhibiting score 8 seizures. We
considered as signiﬁcant P values b0.01.
Data from neurochemistry assays are expressed as mean percent-
ages of control and SEM. These data were submitted to one-way
ANOVA followed by the Newman–Keuls post hoc test.3. Results
3.1. Venom fractionation
Reverse-phase HPLC fractionation of compounds with molecular
masses lower than 3 KDa (net weight=80 mg) resulted in the
chromatographic proﬁle shown in Fig. 1A. We eluted 19 fractions
that were tested for neurochemical activity. In this work, we chose
Parawixin 10, indicated in the chromatogram by an arrow. The
ESI-MS spectrum of Parawixin 10 showed a major molecular ion
peak at m/z 298.7363 Da (M+2H+) with an approximate
molecular mass of 587.5 Da (Fig. 1B), thus conﬁrming its high
purity.3.2. Anticonvulsant activity
Data from anticonvulsant screening of Parawixin 10 for protecting
animals against seizures are illustrated in Fig. 2. The data indicate that
intracerebroventricular microinjection of Parawixin 10 into rats prior
to the administration of kainic acid inhibits seizures in 40, 68, and
100% of animals at doses of 0.5, 1, and 1.5 μg/μL, respectively (χ2[3]=
303.7, Pb0.001) (Fig. 2A), whereas intraperitoneal diazepam at 2 mg/
kg blocked KA-induced seizures in only one animal (16%); it did not
protect animals at other doses (5 and 10 mg/kg of diazepam), and
only decreased the severity of the seizures. In the NMDA assay,
intracerebroventricular Parawixin 10 at 2.5 and 5 μg/μL blocked
seizures in 50 and 100% of animals, respectively (χ2[2]=293.3,
Pb0.0001) (Fig. 2B). No animal was protected against NMDA- or
KA-induced seizures by intravenous diazepam (2, 5, and 10 mg/kg).
Systemic administration of PTZ (80 mg/kg, ip) induced generalized
seizures in all treated animals, which were blocked by pre-
administration of Parawixin 10 (2, 3, and 6 μg/μL) in 50, 7, and
100% of animals, respectively (χ2[3]=323.2, Pb0.0001) (Fig. 2C). In
contrast, generalized seizures evoked by the GABA-mediated Cl–
inﬂux blockade with PTZ were completely abolished by the
administration of diazepam (2 mg/kg), whereas the anticonvulsant
effects of Parawixin 10 were observed only at higher doses. The
anticonvulsant activity of Parawixin 10 exhibited a dose-dependent
proﬁle in all experiments.
In addition, analysis of the latency to seizure onset of unprotected
animals revealed that at lower doses, Parawixin 10 signiﬁcantly
increased latency to KA-induced [F(2,11)=46.48, Pb0.01] and
NMDA-induced [F(2,9)=26,41, P=0.0005] seizures. Latency to
PTZ-induced seizures also increased after the administration of
nonprotecting doses of Parawixin 10. In this case, 3 μg/μL Parawixin
10 increased the latency to seizure onset and generalization [F(3,20)=
47,70, Pb0.0001]. Latencies to seizure onset of seizing animals are listed
in Table 1. It is important to note that the Parawixin 10 dose used to
protect 100% of KA-induced seizures was the lowest dose used
(1.5 μg/μL) to obtain this protection percentage relative to other
convulsants.
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Analysis of spontaneous locomotor activity in the open ﬁeld
revealed differences among the time periods (four time windows:
0–5, 5–10, 10–15, and 15–20 minutes) [F(3,9)=30.369, Pb0.0001],
Parawixin 10 treatments [F(3,11)=13.542, P=0.001], and treat-
ment versus time window [F(9,23)=4.158, P=0.003] (Fig. 3A). A
peak in exploratory activity was observed from 0 to 5 minutes after
all treatments (Pb0.0001), followed by a decrease in exploratory
activity. The administration of any dose of Parawixin 10 exerted a
marked inhibitory effect on exploratory behavior, considering that
there was a marked decrease in the number of line crosses from 5 to
20 minutes after injections (Pb0.001).
Behavioral analysis revealed differences among treatments in the
open-ﬁeld experiments with respect to exploration [F(3,12)=5.967,
P=0.009] and grooming [F(3,12)=33.39, Pb0.0001], whereasinactivity remained equal [F(3,12)=0.573, P=0.643] (Fig. 3B). Post
hoc tests showed that rats treated with10 μg/μL Parawixin 10 spent
more time grooming and did not explore the arena as much as
physiological saline-treated control animals (Pb0.001). Lower doses
of Parawixin 10 did not alter rat behavior in the open-ﬁeld test.3.4. Motor ataxia
Parawixin 10 at any concentration used in the tests was able to
induce motor impairments in the rotarod test. Animals did not fall off
the rod after administration of Parawixin 10 at doses up to 75 μg/μL.
Therefore, the estimated TD50 for Parawixin 10 is NN75 μg/μL, which is
more than 37.5-fold higher than the ED50 for PTZ-induced seizures,
more than77-foldhigher than theED50 forNMDA-induced seizures, and
more than 1071-fold higher than the ED50 for KA-induced seizures.
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Figs. 4A–C are dose–response curves for the effect of Parawixin 10
on [3H]glutamate, [3H]glycine, and [3H]GABA uptake. The results
indicate that in the presence of 10 ng/mL Parawixin 10, there was a
maximum increase of 79% in glutamate uptake (Fig. 4A), whereas
glycine (Fig. 4B) uptake increased by 40% when 1 ng/mL Parawixin 10Table 1
Latency to onset of score 8 seizures evoked by chemoconvulsants after injection of Parawix
Chemical convulsant
(route, dose)
Latency to sezirure onset (s)
Saline Diazepam
2 mg/kg 5 mg/kg 1
Kainic acid (icv, 2.4 μg/μL) 218.85±46.65 162.5±18.87a 237.5±30.65 2
PTZ (ip, 85 mg/kg) 59.88±6.42 — — —
NMDA (icv, 17 μg/μL) 130±39.16 250±56.86a 332±68.72a 3
Note. Mean latencies (± SEM) were submitted to one-way analysis of variance followed by
a Pb0.01, compared with saline.
b Pb0.001, compared with saline.
c —, Absence of seizures.was added to synaptosomes. Finally, Parawixin 10 did not alter GABA
uptake (Fig. 4C) at any of the concentrations used.
4. Discussion
Previous studies on spider venom molecules have demonstrated
the anticonvulsant and neuroprotective activities of these compounds
in several animal models of seizure induction and neuronal damagein 10 and diazepam.
Parawixin 10
0 mg/kg 0.5 μg 1 μg 2 μg 2 μg
71±112.2 1030±141b —c — —
829.5±97.6a 754±214.5a — 1383±18.5b
97±125.0a — 503.5±2.35b 611.5±13.87b —
Student–Newman–Keuls post hoc test.
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inhibitory activity might be attributed to the selective antagonism of
glutamatergic receptors (JsTx toxin [23]), blockade of Na+ (μ-Aga-I to
μ-Aga-IV [24]), and Ca2+ (FTX toxin [25]) cationic channels, inhibition
of glutamate release (PnTx3–6 toxin [26]), enhancement of glutamate
transporters (Parawixin 1 [4]), and inhibition of GABA and glycine
transporters (FrPbAII [5]).
The present work evaluated the effects of a novel compound
isolated from P. bistriata spider venom on chemically induced seizures
and synaptosomal neurotransmitter uptake. Our data showed that
intracerebroventricular administration of Parawixin 10 blocks gener-
alized seizures induced with KA, NMDA, and PTZ, and the anticon-
vulsant dose that blocked KA-induced seizures in 100% of animals was
three times lower than the dose for NMDA-induced seizures and four
times lower than the dose for PTZ-induced seizures. Notwithstanding
the effect on L-Glu uptake in in vitro experiments, these ﬁndings
might indicate a substrate preference in the mode of action of
Parawixin 10, that is, inhibition of excitatory transmission mediatedby non-NMDA receptors. We emphasize that no animals exhibited
seizure-related behaviors when there was protection, all protected
animals had 0 scores with respect to seizures. Interestingly, Parawixin
10 does not induce the locomotor alterations commonly reported
after the administration of glutamatergic receptor antagonists [27].
Another issue is pore formation in the synaptosomal membranes.
However, we ruled out the presence of lesions on neuronmembranes,
because we know that boiled venom does not cause the formation of
pores in these membranes. That was done many times in our
laboratory, using electron microscopy and LDH assay. Moreover,
with respect to synaptosomal preparation integrity, we guaranteed in
each experiment where we used the neurotransmitters "cold"
(nonradioactive) as a control, and these inhibited nonspeciﬁc uptake
by 20%.
In fact, our neurochemistry data indicate that addition of low
concentrations of Parawixin 10 to synaptosomes from rat cerebral
cortices increases L-Glu uptake in 79% of animals, suggesting a high-
afﬁnity mediation [28]. Moreover, we found an alteration in glycine
164 H.A. Fachim et al. / Epilepsy & Behavior 22 (2011) 158–164uptake, although with a maximum increase of 40% at higher doses.
As glutamate transporters regulate the extracellular concentrations of
L-Glu, increases in the activity of these transporters might function as
a compensatory mechanism to counteract chemoconvulsant-induced
hyperexcitation.
Several studies have delineated the role of L-Glu in pathological
processes. In fact, the extrasynaptic concentration of this transmitter
is tightly regulated by high-afﬁnity transporters, the failure of which
may trigger excitotoxicity processes that lead to neuronal death (for
review, see Danbolt [29] and Gadea and López-Colomé [30]). The
presence of excessive glutamate concentrations has been reported in
early neurodegenerative processes in several pathologies such as
ischemia, epilepsy, amyotrophic lateral sclerosis, and Alzheimer's
disease [30,31].
Previous work from our laboratory identiﬁed Parawixin 1, another
compound that acts allosterically over EAAT2, the predominant CNS L-
Glu receptor subtype [4,8]. According to Fontana and co-workers [4],
endovenous administration of Parawixin I protects rat retinal neurons
from ischemic damage in an experimental model of acute glaucoma.
Because of the importance of EAAT2 in the regulation of extracellular
concentrations of glutamate, drugs that target this subtype of
transporter may prevent excitotoxicity without blocking L-Glu
transmission [9].
Another important ﬁnding is that Parawixin 10 increases glycine
uptake. In this regard, Raiteri and co-workers [32] showed that glycine
uptake by the astrocytic transporter, GLYT-1 may induce GABA release
from co-localized synapses, enhancing the inhibitory activity of
Parawixin 10. Another point is the co-localization of GLYT-1 and NMDA
receptors, which suggests that this transporter regulates the activity of
this excitatory receptor [33,34]. Finally, glycine works as a necessary
co-agonist of theNMDAreceptor bybinding to the strychnine-insensitive
site at the NMDA complex, allowing further glutamate activation of this
receptor [35]. Hence, the increase in glycineuptake inparticular synapses
may lead to enhancement an inhibitory activity and decrease of
excitotoxic activity, respectively mediated by GABA and L-Glu.
Themost interesting result of ourwork is rat seizure inhibition, and
many assays can be performed, such as neurochemistry experiments
using speciﬁc L-Glu and Gly antagonists in synaptosomes from
cerebral cortex, to determine whether there would be potentiation
or competition for the same site. Still, it may be necessary, for instance,
to run a full set of tests using Gly and glutamate transporters
transfected in host cell lines such as COS-7 and MDCK.
Preliminary magnetic resonance structural analyses of Parawixin
10 indicate that this compound is probably a polyamine.
Our ﬁndings indicate that Parawixin 10 has an important mode of
action that should be further investigated as it may be a novel tool in
understanding the glutamatergic and glycinergic transmission sys-
tems and diseases associated with these systems.
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